Supplementary information

Enzymatic characterization of PCIF1, the mRNA cap adenosine-N6 methyltransferase, acting on uncapped RNAs

Dan Yu¹, Nan Dai², Eric J. Wolf², Ivan R. Corrêa Jr.², Jujun Zhou¹, Tao Wu³, Robert M. Blumenthal⁴, Xing Zhang^{1,*}, Xiaodong Cheng^{1,*}

From the ¹Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; ²New England Biolabs, Inc, Ipswich, MA 01938 USA; ³Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; ⁴Department of Medical Microbiology and Immunology, and Program in Bioinformatics, The University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA

* Correspondence: XZhang21@mdanderson.org or XCheng5@mdanderson.org

Email addresses:

DY (DYu6@mdanderson.org); ND (Dain@neb.com); EW (ewolf@neb.com);

IC (correa@neb.com); JZ (JZhou12@mdanderson.org); TW (Tao.Wu@bcm.edu);

RMB (Robert.Blumenthal@utoledo.edu); XZ (XZhang21@mdanderson.org);

XC (XCheng5@mdanderson.org)





Figure S1. PCIF1 activity assay. (A) An example of analytic size exclusion chromatography (Superdex 200 Increase 10/300 GL) showing the peak fractions and retention volume. (B) Summary of four fractions and the corresponding enzyme concentrations and specific activity on RNA oligo R2, measured by the velocity of product SAH formation per enzyme molecule [SAH]/[E]. The control enzyme was taken from a previous purification. (C) The specific activity of each fraction. (D-E) Calibration curves for Promega bioluminescence assay as a function of SAH concentrations in the range of (B) below or (E) above 1 μM.






Figure S2. Representative tandem mass spectra of oligo R1 in the presence of (A) SAM or (B) sinfungin.




Figure S3. Representative tandem mass spectra of intact methylated R2 oligos (A-C).




Figure S4. Representative tandem mass spectra of intact methylated R3 oligos (A-C).